Navigation Links
Abviva Engages W.T. Uniack & Co. As Independent Auditor
Date:6/4/2010

SANTA BARBARA, Calif., June 4 /PRNewswire-FirstCall/ -- Abviva, Inc. (Pink Sheets: ABVV), a biomedical company engaged in the development and commercialization of breast cancer related applications of Mammastatin, today provided further details about worldwide patent protection for its breast cancer risk assessment technology.  

Abviva appoints W.T. Uniack & Co. as its independent auditor.  Abviva is working hard to regain compliance and this is the next step.  Uniack will perform the audit for the fiscal years 2008 and 2009.  Abviva is moving as quickly as possible to complete these audits.

"We look forward to building shareholder value by completing these audits and becoming fully OTCBB compliant.  This is the first of many announcements that will demonstrate the Company's dedication to increasing the Company's bottom line as well as shareholder value," said Barrett Evans, CEO of Abviva, Inc.

About Abviva

Abviva, Inc. is a biomedical company engaged in the innovation, development and commercialization of breast cancer related applications of Mammastatin, a growth inhibitory protein discovered at the University of Michigan Cancer Center that demonstrated anti-breast cancer properties. The discovery was developed into a simple breast cancer diagnostic blood test that demonstrated healthy women have high or normal levels of the protein and women with breast cancer have no detectable or very low levels of the protein. Abviva intends to commercialize the Mammastatin Serum Assay as a reference test through its wholly owned subsidiary laboratory under CLIA certification.  

Statements in this press release that are not strictly historical facts are "forward-looking" statements (identified by the words "believe", "estimate", "project", "expect" or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.


'/>"/>
SOURCE Abviva, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
2. Vion Pharmaceuticals Engages Merriman Curhan Ford to Evaluate Strategic Alternatives
3. Secure eHealth, LLC Engages as a Consultant GSI Health Whose Principal and CEO is the Former Senior Advisor to National Coordinator for Health Information Technology
4. Vystar Corporation Engages The Investor Relations Group
5. Speedus Engages Morgan Joseph to Evaluate Strategic Alternatives for Zargis Subsidiary
6. Wound Management Technologies, Inc. Engages Miller Tabak, A National Investment Banking Firm Specializing in the Healthcare Market Space
7. GeoVax Labs Engages The Investor Relations Group
8. Frost & Sullivan: Western European Markets Confirm Undisputed Convenience and Cost Benefit of Custom Procedure Trays
9. Boston Scientific and Johnson & Johnson Announce Settlement of Patent Disputes
10. Tata Interactive Systems Partners With Bersin & Associates for Exclusive Executive Learning Forum - TLF 2009
11. Sigma-Aldrich (Nasdaq: SIAL) Announces Appointment of George Miller as Sr. Vice President, General Counsel & Secretary
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... Association, in partnership with ALS Finding a Cure, is pleased ... track TDP43 aggregation. The successful team(s) with the most developed ... --> --> ALS is ... brain and the spinal cord. Eventually, people with ALS lose ... leads to total paralysis and death within two to five ...
(Date:2/10/2016)... Feb. 10, 2016 Convergence scenarios ... of various technologies that results in diverse ... These opportunities create a cyclical system where ... drives the development of new technologies. ... by technology convergences, which are constantly fostering ...
(Date:2/10/2016)... 10, 2016 Antibacterial Drugs Market - ... - 2023 ", reveals that the global antibacterial drugs market ... to 2023 owing to patent expiries of blockbuster drugs. Even ... during the forecast period, the value is anticipated to decline ... --> Antibacterial Drugs Market - Global Industry Analysis, ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... February 10, 2016 , ... As part of its ongoing ... February 2016. Each webinar features a dynamic expert and thoughtful presentation to give ... patients and facilities. Both events are free to attend, but registration is ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... American Academy of Emergency Medicine , an emergency medicine professional association, ... practice management services . , The American Academy of Emergency Medicine, or AAEM, ...
(Date:2/10/2016)... ... February 10, 2016 , ... The Wickman Agency in ... assist the local community. Pledging to select a new beneficiary every 60 days, ... area. Their goal is to bring community awareness to important local causes by ...
(Date:2/10/2016)... , ... February 10, 2016 , ... 10 Best ... There were three leading bottled water brand owners that topped the list as a ... connectivity and optimize conversion. The premier brand was Tibet 5100, a top notch water ...
(Date:2/10/2016)... ... February 10, 2016 , ... Dr. Jessica Barron, of ... is now accepting new dental patients and families in the North Metro Denver area. ... services from cleanings to cosmetic dentistry, and all in the most relaxing environment. , ...
Breaking Medicine News(10 mins):